Cargando…

The Effect of Sugammadex on Prothrombin and Activated Partial Thromboplastin Time

Sugammadex is routinely used as an effective neuromuscular blockade reversal agent. Several studies have indicated that it may prolong the prothrombin time (PT) and the activated partial thromboplastin time (aPTT). This review gathers the relevant in vivo studies to accumulate knowledge on the subje...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samara, Evangelia, Stamatiou, Konstantinos, Balanika, Marina, Tzimas, Petros
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2021
Materias:	Anesthesiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126340/ https://www.ncbi.nlm.nih.gov/pubmed/34012734 http://dx.doi.org/10.7759/cureus.14521

Ejemplares similares

Genetic Polymorphisms Associated with Prothrombin Time and Activated Partial Thromboplastin Time in Chinese Healthy Population
por: Zhang, Fan, et al.
Publicado: (2022)

Adverse Effects of Sugammadex on the Cardiovascular System
por: Kadiyala, Mamatha, et al.
Publicado: (2023)

Effect of storage conditions on prothrombin time, activated partial thromboplastin time and fibrinogen concentration on canine plasma samples
por: Piccione, Giuseppe, et al.
Publicado: (2010)

The effects of hemolysis on plasma prothrombin time and activated partial thromboplastin time tests using photo-optical method
por: Hernaningsih, Yetti, et al.
Publicado: (2017)

The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma
por: Geng, Chuanying, et al.
Publicado: (2021)

Role of thromboelastography in the evaluation of septic shock patients with normal prothrombin time and activated partial thromboplastin time
por: Kim, Sang-Min, et al.
Publicado: (2021)

Cardiac arrest after administration of sugammadex as neuromuscular blockade reversal agent and full recovery from anesthesia
por: Samara, Evangelia, et al.
Publicado: (2020)

Prothrombin Time and Activated Partial Thromboplastin Time Testing: A Comparative Effectiveness Study in a Million-Patient Sample
por: Capoor, Manu N., et al.
Publicado: (2015)

Risk stratification and prognostic value of prothrombin time and activated partial thromboplastin time among COVID-19 patients
por: Tekle, Esayas, et al.
Publicado: (2022)

Clinical Impact of Sugammadex in the Reversal of Neuromuscular Blockade
por: Goodner, Joshua A, et al.
Publicado: (2021)

Evaluation of Prothrombin Time and Activated Partial Thromboplastin Time in Hypertensive Patients Attending a Tertiary Hospital in Calabar, Nigeria
por: Nnenna Adaeze, Nnamani, et al.
Publicado: (2014)

Activated Partial Thromboplastin Time or Prothrombin Time Prolongation During Rivaroxaban Administration: Clinical Risk Factors and Outcomes Analysis
por: Yuan, Yao, et al.
Publicado: (2023)

Prediction of Poor Outcomes in Patients with Colorectal Cancer: Elevated Preoperative Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT)
por: Zhang, Lin, et al.
Publicado: (2020)

FRACTIONATION OF PLASMA GLOBULIN FOR PROTHROMBIN, THROMBOKINASE, AND ACCESSORY THROMBOPLASTIN
por: Milstone, J. H.
Publicado: (1951)

Assessment of Stability of Prothrombin Time, International Normalized Ratio, and Activated Partial Thromboplastin Time Under Different Storage Conditions in Human Plasma
por: Patil, Parag, et al.
Publicado: (2022)

Nephroprotective Efficacy of Sugammadex in Ischemia-Reperfusion Injury: An Experimental Study in a Rat Model
por: Tercan, Mehmet, et al.
Publicado: (2021)

The Effects of Rocuronium-sugammadex on Fetomaternal Outcomes in Pregnancy Undergoing Electroconvulsive Therapy: A Retrospective Case Series and Literature Review
por: Karahan, Mahmut A, et al.
Publicado: (2019)

Anaphylaxis Induced by Sugammadex in a Patient with Papillary Serous Carcinoma of the Uterine Adnexa Undergoing Exploratory Laparotomy
por: Escher, Allan R, et al.
Publicado: (2019)

Sugammadex to Facilitate Neurologic Assessment in Severely Brain-Injured Patients: A Retrospective Analysis and Practical Guidance
por: Hyland, Sara J, et al.
Publicado: (2022)

Standardization of Coagulation Factor V Reference Intervals, Prothrombin Time, and Activated Partial Thromboplastin Time in Mice for Use in Factor V Deficiency Pathological Models
por: De Pablo-Moreno, Juan A., et al.
Publicado: (2022)

Effect of the reaction temperature on the prothrombin time and the apparent International Normalized Ratio determined with International Standards for thromboplastins
por: Van Den Besselaar, Antonius M. H. P., et al.
Publicado: (2021)

International normalized ratio and activated partial thromboplastin time testing
por: Chornenki, Nicholas L. J., et al.
Publicado: (2022)

Successful Neuromuscular Blockade Reversal Using Sugammadex and Neostigmine Failed to Prevent Myasthenic Crisis After Emergency Surgery: A Case Report
por: Haddad, Daniel, et al.
Publicado: (2022)

Comparative analysis on characteristics of two activated partial thromboplastin time reagents
por: Yasui, Yutaro, et al.
Publicado: (2022)

Isolated Prolongation of Activated Partial Thromboplastin Time: Not Just Bleeding Risk!
por: Santoro, Rita Carlotta, et al.
Publicado: (2023)

Prothrombin Time, Activated Partial Thromboplastin Time, and Fibrinogen Reference Intervals for Inbred Strain 13/N Guinea Pigs (Cavia porcellus) and Validation of Low Volume Sample Analysis
por: Condrey, Jillian A., et al.
Publicado: (2020)

Warfarin Reversal With Four-Factor Prothrombin Complex Concentrate for Left Ventricular Assist Device Conversion Surgery Monitored by TEG6s: A Case Report
por: Ito, Hisakatsu, et al.
Publicado: (2022)

Activated Partial Thromboplastin Time and Mortality in Coronary Artery Bypass Grafting Patients
por: Zhang, HuanRui, et al.
Publicado: (2022)

The Use of Enhanced Recovery After Surgery Protocols and Sugammadex in a Friedreich Ataxia Patient Who Underwent Robotic Surgery: A Case Report of a Patient Who Required No Postoperative Opioids and Was Discharged Home Earlier Than Anticipated
por: Russo, Lori P, et al.
Publicado: (2022)

Diabetes Mellitus Is Associated with Shortened Activated Partial Thromboplastin Time and Increased Fibrinogen Values
por: Zhao, Ying, et al.
Publicado: (2011)

Sequential thrombosis and bleeding in a woman with a prolonged activated partial thromboplastin time
por: Spencer, Akpan, et al.
Publicado: (2011)

Coronary Artery Disease Presentation and Its Association with Shortened Activated Partial Thromboplastin Time
por: Sotoudeh Anvari, Maryam, et al.
Publicado: (2018)

Falsely prolonged activated partial thromboplastin time – a pre- and post-analytical issue
por: Gils, Charlotte, et al.
Publicado: (2018)

An Evaluation of Hemostatic Abnormalities in Patients With Hemophilia According to the Activated Partial Thromboplastin Time Waveform
por: Katayama, Haruna, et al.
Publicado: (2018)

Reagent Effects on the Activated Partial Thromboplastin Time Clot Waveform Analysis: A Multi-Centre Study
por: Wong, Wan Hui, et al.
Publicado: (2023)

Pneumatic tube system transport does not alter platelet function in optical and whole blood aggregometry, prothrombin time, activated partial thromboplastin time, platelet count and fibrinogen in patients on anti-platelet drug therapy
por: Enko, Dietmar, et al.
Publicado: (2017)

Comparing the Effects of General Versus Regional Anesthesia on Postoperative Mortality in Total and Partial Hip Arthroplasty
por: Khan, Irfan A, et al.
Publicado: (2021)

Prolonged activated partial thromboplastin time secondary to factor XII deficiency in two surgical patients
por: Moiz, Bushra, et al.
Publicado: (2021)

Activated partial thromboplastin time waveform analysis as specific sepsis marker in cardiopulmonary bypass surgery
por: Schneider, Christian P, et al.
Publicado: (2010)

A Patient with a Prolonged Activated Partial Thromboplastin Time and a Deep Intracerebral Haemorrhage
por: Schindhelm, Roger K., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_3amfvc0fc58vl8062useupac62